Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 129 Carcinoma, Renal Cell 36 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Neoplasms 27 Cholangiocarcinoma 23 Endometrial Neoplasms 19 Liver Neoplasms 16 Melanoma 15 Thyroid Neoplasms 13 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Biliary Tract Neoplasms 12 Neoplasm Metastasis 9 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Ovarian Neoplasms 8 Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Triple Negative Breast Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Small Cell Lung Carcinoma 5 Neuroendocrine Tumors 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Adenocarcinoma 4 Thyroid Cancer, Papillary 3 Solid Tumors 3

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HCC × lenvatinib × Clear all

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡